Themis and MSD (trademark of Merck & Co., Inc., Kenilworth, N.J., USA) today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications.
by eazee-designstudio
Themis and ABL Europe, a global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), a subsidiary of the French bioindustrial group Institut Mérieux, announced today that they have signed an agreement under which ABL will manufacture Themis’ vaccine candidate in preparation for clinical trials. The vaccine is being developed using a proprietary measles virus vaccine platform technology, which is licensed exclusively to Themis by the world-renowned Institut Pasteur in Paris.
